Fruquintinib API Manufacturer and Supplier | CAS 1194506-26-7 - Dr. Reddy's
Chi-Med announces first commercial launch of fruquintinib capsules (Elunate)
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial | SpringerLink
Untitled
Hutchison China MediTech — An emerging global biopharma - Edison Group
Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA's Fast Track Designation
HMP Receives Approval For Elunate | Contract Pharma
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China | BMC Cancer | Full Text
China approves first "Made in China" cancer drug
Selleck Chemical LLC Fruquintinib (HMPL-013) 5mg 1194506-26-7, Quantity: | Fisher Scientific
Efficacy of fruquintinib confirmed in refractory metastatic colorectal cancer - Medical Update Online
ESMO: Eyeing Bayer, Hutchmed touts 'practice-changing' CRC win
Hutchmed confirms new drug application for fruquintinib in Japan - Sharecast.com
HUTCHMED
StudyPages - Clinical trial with Fruquintinib in patients with Metastatic Colorectal Cancer who has not responded to previous treatment
China Approves Home-Grown Colon Cancer Drug - Asian Scientist Magazine
Full article: The clinical application of fruquintinib on colorectal cancer
HUTCHMED
Fruquintinib significantly extends survival in refractory metastatic colorectal cancer
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study - The Lancet
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ ( fruquintinib) for Previously Treated Metastatic Colorectal Cancer
Fruquintinib: First Global Approval | SpringerLink
Fruquintinib - Wikipedia
Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer
